Want to see FR:ALMDT full AI Analyst Report?

Median Technologies (ALMDT) Price & Analysis

20 Followers

ALMDT Stock Chart & Stats

€4.04

€0.10(2.35%)

At close: Jul 31 4:00 PM EDT

€4.04

€0.10(2.35%)

Day’s Range― - ―

52-Week Range€1.96 - €7.27

Previous CloseN/A

Volume515.80K

Average Volume (3M)465.96K

Market Cap

€202.66M

Enterprise Value€180.92

Total Cash (Recent Filing)€18.41M

Total Debt (Recent Filing)€21.76M

Price to Earnings (P/E)―

Beta0.84

Next Earnings

Oct 15, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.15

Shares Outstanding49,048,060

10 Day Avg. Volume398,206

30 Day Avg. Volume465,957

Financial Highlights & Ratios

PEG Ratio0.16

Price to Book (P/B)-4.95

Price to Sales (P/S)7.45

P/FCF Ratio-9.58

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.44

Revenue Forecast (FY)€25.43M

Bulls Say, Bears Say

Bulls Say

Revenue Growth MomentumModest but accelerating revenue growth (21.5% in 2025) indicates the company is gaining commercial traction in clinical imaging services and software. Sustained top-line expansion can enable operating leverage, help absorb fixed R&D/platform costs, and support a longer-term path toward improved margins and scale.

Specialized Oncology Imaging Services & SoftwareMedian’s business model—delivering imaging analytics and software to biopharma and CROs—matches durable, contract-driven demand from oncology trials. These engagements are often multi-site and recurring, creating sticky client relationships and predictable revenue streams that underpin medium-term commercial stability.

AI-driven Imaging ExpertiseProprietary AI and radiomics capabilities position the company within a structural growth market for oncology imaging. Algorithmic differentiation and trial-derived data can form a competitive moat; successful regulatory clearance and clinical adoption would enable scalable licensing and higher-margin product revenue over time.

Bears Say

Deep And Persistent UnprofitabilityDespite revenue gains, the company remains deeply loss-making with sharply negative gross profit and recurring net losses. Persistent unprofitability drains resources needed for commercialization and R&D, forcing reliance on external capital and limiting the firm’s ability to self-fund strategic initiatives over the medium term.

Negative Equity / Weak Capital BaseA multi-year negative shareholders' equity position signals a structurally weakened balance sheet. This reduces financial flexibility, increases insolvency and covenant risk, and makes it harder to obtain non-dilutive financing, constraining the company’s ability to absorb shocks or invest aggressively in growth.

Consistent Negative Operating Cash FlowConsistently negative operating cash flow implies ongoing cash burn to fund operations and growth. This persistent funding gap raises refinancing and dilution risk, shortens runway for commercialization efforts, and can interrupt product development or market expansion absent reliable external funding.

Median Technologies News

Median Technologies strikes global Canon partnership to scale AI lung cancer screening

Median Technologies ( ($FR:ALMDT) ) has issued an announcement. Median Technologies has signed a global strategic commercial partnership...

9d ago

Median Technologies strengthens finances as eyonis lung cancer AI wins U.S. and EU approval

Median Technologies ( ($FR:ALMDT) ) has shared an update. Median Technologies, a specialist in AI-based medical imaging software...

17d ago

ALMDT FAQ

What was Median Technologies’s price range in the past 12 months?

Median Technologies lowest stock price was €1.96 and its highest was €7.27 in the past 12 months.

What is Median Technologies’s market cap?

Median Technologies’s market cap is €202.66M.

When is Median Technologies’s upcoming earnings report date?

Median Technologies’s upcoming earnings report date is Oct 15, 2026 which is in 68 days.

How were Median Technologies’s earnings last quarter?

Median Technologies released its earnings results on Apr 23, 2026. The company reported -€0.677 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Median Technologies overvalued?

According to Wall Street analysts Median Technologies’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Median Technologies pay dividends?

Median Technologies does not currently pay dividends.

What is Median Technologies’s EPS estimate?

Median Technologies’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Median Technologies have?

Median Technologies has 49,048,060 shares outstanding.

What happened to Median Technologies’s price movement after its last earnings report?

Median Technologies reported an EPS of -€0.677 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.957%.

Which hedge fund is a major shareholder of Median Technologies?

Currently, no hedge funds are holding shares in FR:ALMDT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Median Technologies

Headquartered in Valbonne, France, Median Technologies S.A. was established in 2002. This company specializes in developing and commercializing advanced software and platforms designed for medical image analysis. Its reach extends globally, serving markets in France, the United States, Canada, the United Kingdom, China, and beyond. Among its key offerings is iBiops, an innovative, AI-powered software classified as a medical device. This solution comprehensively integrates and optimizes the entire medical imaging workflow. Additionally, Median Technologies provides iSee, a service dedicated to image analysis specifically for clinical trials. Furthermore, the company delivers extensive imaging contract research organization (CRO) services. These encompass a wide range of activities, from study initiation and the management of both image and clinical data, to scientific advisory, independent reviews, image data processing, site support, and final study close-out. Solidifying its commitment to research, Median Technologies maintains a collaborative agreement with the University of California.